No Prescription |
 |
 | ||
|
ROZUCOR Crestor |
|
| ||
No Prescription » Prescription Drugs 14 » ROZUCOR Crestor Rosuvastatin is used for: Lowering cholesterol and triglyceride levels and increasing "good" cholesterol (high-density lipoprotein [HDL]) levels in patients who have also adopted lifestyle changes (eg diet and exercise). Rosuvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body. It works by reducing levels of "bad" cholesterol (low-density lipoprotein or LDL) and triglycerides in the blood while increasing levels of "good" cholesterol (high-density lipoprotein or HDL).Rosuvastatin is used to treat high cholesterol. Lowering your cholesterol can help prevent heart disease and hardening of the arteries conditions that can lead to heart attack stroke and vascular disease. Buy ROZUCOR Crestor and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About ROZUCOR Crestor: Product Type: Prescription Drugs 14 ROZUCOR ( Crestor Generic Rosuvastatin ) ROZUCOR (Crestor Generic Rosuvastatin) Crestor Generic Rosuvastatin 10mg Crestor Generic Rosuvastatin ROZUCOR
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
